Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Drugs & Aging
Published in: Drugs & Aging 7/2007

01-07-2007 | Therapy In Practice

Acute Exacerbations of Chronic Bronchitis in Elderly Patients

Pathogenesis, Diagnosis and Management

Authors: Don Hayes Jr, Dr Keith C. Meyer

Published in: Drugs & Aging | Issue 7/2007

Login to get access

Abstract

Chronic bronchitis (CB) is a disorder that is characterised by chronic mucus production. This disorder is called chronic obstructive pulmonary disease (COPD) when airflow obstruction is present. The majority of patients with COPD, which often goes undiagnosed or inadequately treated in the elderly, have symptoms consistent with CB. The clinical course of CB is usually punctuated by periodic acute exacerbations linked to infections caused by viral and typical or atypical bacterial pathogens. Acute exacerbations of chronic bronchitis (AECB) often lead to a decline in lung function and poor quality of life in association with increased risk of mortality and a significant economic impact on the healthcare system and society because of the direct costs of hospitalisations. In elderly individuals with COPD, co-morbidities play a vital role as determinants of health status and prognosis. Failure to eradicate infecting pathogens contributes to persistence of infection and inflammation that requires repeated courses of therapy and hospitalisation. Stratifying patients with AECB according to symptoms, degree of pulmonary function impairment and risk factors for poor outcome can help clinicians choose empirical antimicrobial chemotherapy regimens that are most likely to result in treatment success. Failure to cover likely pathogens associated with episodes of AECB can lead to lengthy hospital admissions and significant declines in functional status for elderly patients. Fluoroquinolones may provide the best therapeutic option for elderly patients with COPD who have complicated underlying CB but who are sufficiently stable to be treated in the outpatient setting. Optimised treatment for stable outpatients with CB may diminish the frequency of AECB, and effective antimicrobial therapy for AECB episodes can significantly diminish healthcare costs and maintain quality of life in the elderly patient.
Literature
1.
Petty TL. Definitions in chronic obstructive pulmonary disease. Clin Chest Med 1990; 11(3): 363–73PubMed
2.
Anto JM, Vermeire P, Vestbo J, et al. Epidemiology of chronic obstructive pulmonary disease. Eur Respir J 2001; 17(5): 982–94PubMedCrossRef
3.
Hurd S. The impact of COPD on lung health worldwide: epidemiology and incidence. Chest 2000; 117(2 Suppl.): 1–4SCrossRef
4.
Halbert RJ, Isonaka S, George D, et al. Interpreting COPD prevalence estimates: what is the true burden of disease? Chest 2003; 123(5): 1684–92PubMedCrossRef
5.
Pauwels RA, Buist AS, Calverley PM, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 2001; 163(5): 1256–76PubMed
6.
Fabbri LM, Hurd SS, GOLD Scientific Committee. Global strategy for the diagnosis, management and prevention of COPD: 2003 update. Eur Respir J 2003; 22(1): 1–2PubMedCrossRef
7.
Celli BR, MacNee W, ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23(6): 932–46PubMedCrossRef
8.
Sterk PJ. Let’s not forget: the GOLD criteria for COPD are based on post-bronchodilator FEV1. Eur Respir J 2004 Apr; 23(4): 497–8PubMedCrossRef
9.
Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, November 1986. Am Rev Respir Dis 1987; 136(1): 225–44CrossRef
10.
British Thoracic Society. British Thoracic Society guidelines for the management of chronic obstructive pulmonary disease. Thoracic 1997; Suppl. 5: S1–28
11.
Engström CP, Persson LO, Larsson S, et al. Health-related quality of life in COPD: why both disease-specific and generic measures should be used. Eur Respir J 2001; 18(1): 69–76PubMedCrossRef
12.
13.
Wouters EF. Economic analysis of the Confronting COPD survey: an overview of results. Respir Med 2003; Suppl. C: S3–14
14.
15.
Peterson DD, Fishman AP. The lungs in later life. In: Fishman AP, editor. Pulmonary disease and disorders: update 1. New York: McGraw-Hill, 1982: 123–36
16.
Enright PL, Kronmal RA, Manolio TA, et al. Respiratory muscle strength in the elderly: correlates and reference values. Cardiovascular Health Study Research Group. Am J Respir Crit Care Med 1994; 149 (2 Pt 1): 430–8PubMed
17.
Peterson DD, Pack AI, Silage DA, et al. Effects of aging on ventilatory and occlusion pressure responses to hypoxia and hypercapnia. Am Rev Respir Dis 1981; 124(4): 387–91PubMed
18.
Tack M, Altose MD, Cherniack NS. Effect of aging on the perception of resistive ventilatory loads. Am Rev Respir Dis 1982; 126(3): 463–7PubMed
19.
Ancoli-Israel S, Coy T. Are breathing disturbances in elderly equivalent to sleep apnea syndrome? Sleep 1994; 17(1): 77–83PubMed
20.
21.
22.
23.
Zhang P, Summer WR, Bagby GJ, et al. Innate immunity and pulmonary host defense. Immunol Rev 2000; 173: 39–51PubMedCrossRef
24.
Masten BJ. Initiation of lung immunity: the afferent limb and the role of dendritic cells. Semin Respir Crit Care Med 2004; 25(1): 11–20PubMedCrossRef
25.
Ginaldi L, De Martinis M, D’Ostilio A, et al. Immunological changes in the elderly. Aging Clin Exp Res 1999; 11: 281–6
26.
Meyer KC. The role of immunity in susceptibility to respiratory infection in the aging lung. Respir Physiol 2001; 128(1): 23–31PubMedCrossRef
27.
Nicoletti C, Borghesi-Nicoletti C, Yang XH, et al. Repertoire diversity of antibody response to bacterial antigens in aged mice: II. Phosphorylcholine-antibody in young and aged mice differ in both VH/VL gene repertoire and in specificity. J Immunol 1991 Oct 15; 147(8): 2750–5PubMed
28.
Liu J, Wang S, Liu H, et al. The monitoring biomarker for immune function of lymphocytes in the elderly. Mech Ageing Dev 1997; 94(1–3): 177–82PubMedCrossRef
29.
Song H, Price PW, Cerny J. Age-related changes in antibody repertoire: contribution from T cells. Immunol Rev 1997; 160: 55–62PubMedCrossRef
30.
Flurkey K, Stadecker M, Miller RA. Memory T lymphocyte hyporesponsiveness to non-cognate stimuli: a key factor in age-related immunodeficiency. Eur J Immunol 1992; 22(4): 931–5PubMedCrossRef
31.
Li SP, Verma S, Miller RA. Age-related defects in T cell expression of CD40 ligand and induction of in vitro B cell activation. Aging Immunol Infect Dis 1995; 6: 79–93
32.
Cakman I, Rohwer J, Schutz RM, et al. Dysregulation between TH1 and TH2 T cell subpopulations in the elderly. Mech Ageing Dev 1996; 87(3): 197–209PubMedCrossRef
33.
Zhou T, Edwards 3rd CK, Mountz JD. Prevention of age-related T cell apoptosis defect in CD2-fas-transgenic mice. J Exp Med 1995; 182(1): 129–37PubMedCrossRef
34.
Jackola DR, Ruger JK, Miller RA. Age-associated changes in human T cell phenotype and function. Aging (Milano) 1994; 6(1): 25–34
35.
Linton PJ, Haynes L, Tsui L, et al. From naive to effector: alterations with aging. Immunol Rev 1997; 160: 9–18PubMedCrossRef
36.
Miller RA, Garcia G, Kirk CJ, et al. Early activation defects in T lymphocytes from aged mice. Immunol Rev 1997; 160: 79–90PubMedCrossRef
37.
38.
Kim WD, Kim WS, Koh Y, et al. Abnormal peripheral blood T-lymphocyte subsets in a subgroup of patients with COPD. Chest 2002; 122(2): 437–44PubMedCrossRef
39.
Costabel U, Maier K, Teschler H, et al. Local immune components in chronic obstructive pulmonary disease. Respiration 1992; 59Suppl. 1: 17–9PubMedCrossRef
40.
Robbins CS, Dawe DE, Goncharova SI, et al. Cigarette smoke decreases pulmonary dendritic cells and impacts antiviral immune responsiveness. Am J Respir Cell Mol Biol 2004; 30(2): 202–11PubMedCrossRef
41.
Schleimer RP. Innate immune responses and chronic obstructive pulmonary disease: “Terminator” or “Terminator 2”? Proc Am Thorac Soc 2005; 2(4): 342–6; discussion 371–2PubMedCrossRef
42.
Sabroe I, Parker LC, Dockrell DH, et al. Targeting the networks that underpin contiguous immunity in asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 175(4): 306–11PubMedCrossRef
43.
Pons J, Sauleda J, Regueiro V, et al. Expression of Toll-like receptor 2 is up-regulated in monocytes from patients with chronic obstructive pulmonary disease. Respir Res 2006; 7(1): 64PubMedCrossRef
44.
Marc MM, Korosec P, Kosnik M, et al. Complement factors c3a, c4a, and c5a in chronic obstructive pulmonary disease and asthma. Am J Respir Cell Mol Biol 2004; 31(2): 216–9PubMedCrossRef
45.
Kosmas EN, Zorpidou D, Vassilareas V, et al. Decreased C4 complement component serum levels correlate with the degree of emphysema in patients with chronic bronchitis. Chest 1997; 112(2): 341–7PubMedCrossRef
46.
Guo X, Lin HM, Lin Z, et al. Surfactant protein gene A, B, and D marker alleles in chronic obstructive pulmonary disease of a Mexican population. Eur Respir J 2001; 18(3): 482–90PubMedCrossRef
47.
Yang IA, Seeney SL, Wolter JM, et al. Mannose-binding lectin gene polymorphism predicts hospital admissions for COPD infections. Genes Immun 2003; 4(4): 269–74PubMedCrossRef
48.
Gan WQ, Man SF, Senthilselvan A, et al. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 2004; 59(7): 574–80PubMedCrossRef
49.
Sin DD, Lacy P, York E, et al. Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004; 170(7): 760–5PubMedCrossRef
50.
Mullen JB, Wright JL, Wiggs BR, et al. Reassessment of inflammation of airways in chronic bronchitis. BMJ (Clin Res Ed) 1985; 291(6504): 1235–9CrossRef
51.
Saetta M, Di Stefano A, Maestrelli P, et al. Activated T-lymphocytes and macrophages in bronchial mucosa of subjects with chronic bronchitis. Am Rev Respir Dis 1993; 147(2): 301–6PubMed
52.
O’Shaughnessy TC, Ansari TW, Barnes NC, et al. Inflammation in bronchial biopsies of subjects with chronic bronchitis: inverse relationship of CD8+ T lymphocytes with FEV1. Am J Respir Crit Care Med 1997; 155(3): 852–7PubMed
53.
Keatings VM, Collins PD, Scott DM, et al. Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med 1996; 153(2): 530–4PubMed
54.
Yamamoto C, Yoneda T, Yoshikawa M, et al. Airway inflammation in COPD assessed by sputum levels of interleukin-8. Chest 1997; 112(2): 505–10PubMedCrossRef
55.
Beeh KM, Beier J, Kornmann O, et al. Long-term repeatability of induced sputum cells and inflammatory markers in stable, moderately severe COPD. Chest 2003; 123(3): 778–83PubMedCrossRef
56.
Mueller R, Chanez P, Campbell AM, et al. Different cytokine patterns in bronchial biopsies in asthma and chronic bronchitis. Respir Med 1996; 90(2): 79–85PubMedCrossRef
57.
Hill AT, Bayley D, Stockley RA. The interrelationship of sputum inflammatory markers in patients with chronic bronchitis. Am J Respir Crit Care Med 1999; 160(3): 893–8PubMed
58.
Meyer KC, Rosenthal NS, Soergel P, et al. Neutrophils and low-grade inflammation in the seemingly normal aging human lung. Mech Ageing Dev 1998; 104(2): 169–81PubMedCrossRef
59.
Rahman I, Adcock IM. Oxidative stress and redox regulation of lung inflammation in COPD. Eur Respir J 2006; 28(1): 219–42PubMedCrossRef
60.
Moodie FM, Marwick JA, Anderson CS, et al. Oxidative stress and cigarette smoke alter chromatin remodeling but differentially regulate NF-kappaB activation and proinflammatory cytokine release in alveolar epithelial cells. FASEB J 2004; 18(15): 1897–9PubMed
61.
Rogers DF. Airway goblet cells: responsive and adaptable frontline defenders. Eur Respir J 1994; 7(9): 1690–706PubMedCrossRef
62.
Stockley RA. Neutrophils and protease/antiprotease imbalance. Am J Respir Crit Care Med 1999 Nov; 160 (5 Pt 2): S49–52PubMed
63.
Wright JL, Lawson L, Pare PD, et al. The structure and function of the pulmonary vasculature in mild chronic obstructive pulmonary disease: the effect of oxygen and exercise. Am Rev Respir Dis 1983; 128(4): 702–7PubMed
64.
Peinado VI, Barbera JA, Abate P, et al. Inflammatory reaction in pulmonary muscular arteries of patients with mild chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 159 (5 Pt 1): 1605–11PubMed
65.
Riley DJ, Thakker-Varia S, Poiani GJ, et al. Vascular remodeling. In: Crystal RG, West JB, Barnes PJ, et al., editors. The lung: scientific foundations. Philadelphia (PA): Lippincott-Raven, 1977: 1589–97
66.
Wanner A. The role of mucus in chronic obstructive pulmonary disease. Chest 1990; 97(2 Suppl.): 11–15S
67.
MacNee W. Pathophysiology of cor pulmonale in chronic obstructive pulmonary disease: part one. Am J Respir Crit Care Med 1994; 150(3): 833–52PubMed
68.
MacNee W. Pathophysiology of cor pulmonale in chronic obstructive pulmonary disease: part two. Am J Respir Crit Care Med 1994; 150(4): 1158–68PubMed
69.
Pelkonen M, Notkola IL, Nissinen A, et al. Thirty-year cumulative incidence of chronic bronchitis and COPD in relation to 30-year pulmonary function and 40-year mortality: a follow-up in middle-aged rural men. Chest 2006; 130(4): 1129–37PubMedCrossRef
70.
Ganrot PO, Laurell CB, Eriksson S. Obstructive lung disease and trypsin inhibitors in alpha-1-antitrypsin deficiency. Scand J Clin Lab Invest 1967; 19(3): 205–8PubMedCrossRef
71.
Carette MF, Mayaud C, Valade S, et al. Pulmonary emphysema, hepatic lesions, and insulin-dependent diabetes in a patient with alpha-1-antitrypsin (Pi ZZ) deficiency (author’s transi) [in French]. Ann Med Interne (Paris) 1980; 131(6): 349–52
72.
Elliott PR, Bilton D, Lomas DA. Lung polymers in Z alphalantitrypsin deficiency-related emphysema. Am J Respir Cell Mol Biol 1998; 18(5): 670–4PubMed
73.
Stein CE, Kumaran K, Fall CH, et al. Relation of fetal growth to adult lung function in south India. Thorax 1997; 52(10): 895–9PubMedCrossRef
74.
Todisco T, de Benedictis FM, Iannacci L, et al. Mild prematurity and respiratory functions. Eur J Pediatr 1993; 152(1): 55–8PubMedCrossRef
75.
Tager IB, Segal MR, Speizer FE, et al. The natural history of forced expiratory volumes: effect of cigarette smoking and respiratory symptoms. Am Rev Respir Dis 1988; 138(4): 837–49PubMedCrossRef
76.
Silverman EK, Speizer FE. Risk factors for the development of chronic obstructive pulmonary disease. Med Clin North Am 1996; 80(3): 501–22PubMedCrossRef
77.
78.
DeMeo DL, Silverman EK. Genetics of chronic obstructive pulmonary disease. Semin Respir Crit Care Med 2003; 24(2): 151–60PubMedCrossRef
79.
Leuenberger P, Schwartz J, Ackermann-Liebrich U, et al. Passive smoking exposure in adults and chronic respiratory symptoms (SAPALDIA study): Swiss Study on Air Pollution and Lung Diseases in Adults, SAPALDIA Team. Am J Respir Crit Care Med 1994; 150 (5 Pt 1): 1222–8PubMed
80.
Dayal HH, Khuder S, Sharrar R, et al. Passive smoking in obstructive respiratory disease in an industrialized urban population. Environ Res 1994; 65(2): 161–71PubMedCrossRef
81.
Kauffmann F, Drouet D, Lellouch J, et al. Twelve years spirometric changes among Paris area workers. Int J Epidemiol 1979; 8(3): 201–12PubMedCrossRef
82.
Pandey MR. Prevalence of chronic bronchitis in a rural community of the Hill Region of Nepal. Thorax 1984; 39(5): 331–6PubMedCrossRef
83.
Pandey MR. Domestic smoke pollution and chronic bronchitis in a rural community of the Hill Region of Nepal. Thorax 1984; 39(5): 337–9PubMedCrossRef
84.
Behera D, Jindal SK. Respiratory symptoms in Indian women using domestic cooking fuels. Chest 1991; 100(2): 385–8PubMedCrossRef
85.
Perez-Padilla R, Regalado J, Vedal S, et al. Exposure to biomass smoke and chronic airway disease in Mexican women: a case-control study. Am J Respir Crit Care Med 1996; 154 (3 Pt 1): 701–6PubMed
86.
Dennis RJ, Maldonado D, Norman S, et al. Woodsmoke exposure and risk for obstructive airways disease among women. Chest 1996; 109(1): 115–9PubMedCrossRef
87.
Peabody JW, Riddell TJ, Smith KR, et al. Indoor air pollution in rural China: cooking fuels, stoves, and health status. Arch Environ Occup Health 2005; 60(2): 86–95PubMedCrossRef
88.
Hogg JC. Childhood viral infection and the pathogenesis of asthma and chronic obstructive lung disease. Am J Respir Crit Care Med 1999; 160 (5 Pt 2): S26–8PubMed
89.
Johnston ID. Effect of pneumonia in childhood on adult lung function. J Pediatr 1999; 135 (2 Pt 2): 33–7PubMed
90.
Shaheen SO, Barker DJ, Holgate ST. Do lower respiratory tract infections in early childhood cause chronic obstructive pulmonary disease? Am J Respir Crit Care Med 1995; 151(5): 1649–51; discussion 1651–2PubMed
91.
Welle I, Eide GE, Gulsvik A, et al. Pulmonary gas exchange and educational level: a community study. Eur Respir J 2004; 23(4): 583–8PubMedCrossRef
92.
Koster A, Bosma H, Kempen GI, et al. Socioeconomic inequalities in mobility decline in chronic disease groups (asthma/COPD, heart disease, diabetes mellitus, low back pain): only a minor role for disease severity and comorbidity. J Epidemiol Community Health 2004; 58(10): 862–9PubMedCrossRef
93.
Power C, Hypponen E, Smith GD. Socioeconomic position in childhood and early adult life and risk of mortality: a prospective study of the mothers of the 1958 British birth cohort. Am J Public Health 2005; 95(8): 1396–402PubMedCrossRef
94.
95.
96.
Miravitlles M, Murio C, Guerrero T, et al. Costs of chronic bronchitis and COPD: a 1-year follow-up study. Chest 2003; 123(3): 784–91PubMedCrossRef
97.
98.
Anthonisen NR, Connett JE, Kiley JP, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1: the Lung Health Study. JAMA 1994; 272(19): 1497–505PubMedCrossRef
99.
Pauwels RA, Lofdahl CG, Laitinen LA, et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking: European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med 1999; 340(25): 1948–53PubMedCrossRef
100.
Vestbo J, Sorensen T, Lange P, et al. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 1999; 353(9167): 1819–23PubMedCrossRef
101.
Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 2000; 343(26): 1902–9CrossRef
102.
Burge PS, Calverley PM, Jones PW, et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000; 320(7245): 1297–303PubMedCrossRef
103.
Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease: American Thoracic Society. Am J Respir Crit Care Med 1995; 152 (5 Pt 2): S77–121
104.
Saint S, Bent S, Vittinghoff E, et al. Antibiotics in chronic obstructive pulmonary disease exacerbations: a meta-analysis. JAMA 1995; 273(12): 957–60PubMedCrossRef
105.
Anthonisen NR, Manfreda J, Warren CP, et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987; 106(2): 196–204PubMed
106.
Martinez FJ. Acute exacerbations of chronic bronchitis: diagnosis and therapy. J Clin Outcomes Manage 2004; 11: 659–73
107.
Connolly MJ, Lowe D, Anstey K, et al. Admissions to hospital with exacerbations of chronic obstructive pulmonary disease: effect of age related factors and service organization. Thorax 2006; 61: 843–8PubMedCrossRef
108.
Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. Chest 2000; 117: 398–401SCrossRef
109.
Ball P. Acute infective exacerbations of chronic bronchitis. Q J Med 1995; 88: 61–8
110.
Balter MS, La Forge J, Low DE, et al. Canadian guidelines for the management of acute exacerbations of chronic bronchitis. Can Respir J 2003; 10Suppl. B: 3–32B
111.
Sethi S. Infectious etiology of acute exacerbations of chronic bronchitis. Chest 2000; 117Suppl. 2: 380–385SCrossRef
112.
Monso E, Ruiz J, Rosell A, et al. Bacterial infection in chronic obstructive pulmonary disease: a study of stable and exacerbated outpatients using the protected specimen brush. Am J Respir Crit Care Med 1995; 152 (4 Pt 1): 1316–20PubMed
113.
Pela R, Marchesani F, Agostinelli C, et al. Airways microbial flora in COPD patients in stable clinical conditions and during exacerbations: a bronchoscopic investigation. Monaldi Arch Chest Dis 1998; 53(3): 262–7PubMed
114.
Soler N, Torres A, Ewig S, et al. Bronchial microbial patterns in severe exacerbations of chronic obstructive pulmonary disease (COPD) requiring mechanical ventilation. Am J Respir Crit Care Med 1998; 157 (5 Pt 1): 1498–505PubMed
115.
Miravitlles M, Espinosa C, Fernandez-Laso E, et al. Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD: Study Group of Bacterial Infection in COPD. Chest 1999; 116(1): 40–6PubMedCrossRef
116.
Eller J, Ede A, Schaberg T, et al. Infective exacerbations of chronic bronchitis: relation between bacteriologic etiology and lung function. Chest 1998; 113(6): 1542–8PubMedCrossRef
117.
Blasi F, Tarsia P, Aliberti S. Strategic targets of essential host-pathogen interactions. Respiration 2005; 72(1): 9–25PubMedCrossRef
118.
Berenson CS, Murphy TF, Wrona CT, et al. Outer membrane protein P6 of nontypeable Haemophilus influenzae is a potent and selective inducer of human macrophage proinflammatory cytokines. Infect Immun 2005; 73: 2728–35PubMedCrossRef
119.
Shuto T, Xu H, Wang B, et al. Activation of NF-kappa B by nontypeable Hemophilus influenzae is mediated by toll-like receptor 2-TAK1-dependent NIK-IKK alpha/beta-I kappa B alpha and MKK3/6-p38 MAP kinase signaling pathways in epithelial cells. Proc Natl Acad Sci U S A 2001; 98: 8774–9PubMedCrossRef
120.
Hurst JR, Perera WR, Wilkinson TM, et al. Systemic and upper and lower airway inflammation at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006; 173: 71–8PubMedCrossRef
121.
Grossman RF. Guidelines for the treatment of acute exacerbations of chronic bronchitis. Chest 1997; 112(6 Suppl.): 310–313SCrossRef
122.
O’Donnell DE, Hernandez P, Aaron S, et al. Canadian Thoracic Society COPD guidelines: summary of highlights for family doctors [in French]. Can Respir J 2003; 10(6): 316–9PubMed
123.
Niederman MS. Antibiotic therapy of exacerbations of chronic bronchitis. Semin Respir Infect 2000; 15: 59–70PubMedCrossRef
124.
Murphy TF, Sethi S. Chronic obstructive pulmonary disease: role of bacteria and guide to antibacterial selection in the older patient. Drugs Aging 2002; 19: 761–75PubMedCrossRef
125.
Adams SG, Anzueto A. Antibiotic therapy in acute exacerbations of chronic bronchitis. Semin Respir Infect 2000; 15: 234–47PubMedCrossRef
126.
Pfaller MA, Ehrhardt AF, Jones RN. Frequency of pathogen occurrence and antimicrobial susceptibility among community-acquired respiratory tract infections in the respiratory surveillance program study: microbiology from the medical office practice environment. Am J Med 2001; 111: 4–12SCrossRef
127.
Wilson R, Allegra L, Huchon G, et al. Short-term and long-term outcomes of moxifloxacin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitis. Chest 2004; 125(3): 953–64PubMedCrossRef
128.
Martinez FJ, Grossman RF, Zadeikis N, et al. Patient stratification in the management of acute bacterial exacerbation of chronic bronchitis: the role of levofloxacin 750 mg. Eur Respir J 2005; 25(6): 1001–10PubMedCrossRef
129.
Destache CJ, Dewan N, O’Donohue WJ, et al. Clinical and economic considerations in the treatment of acute exacerbations of chronic bronchitis. J Antimicrob Chemother 1999; 43Suppl. A: 107–13PubMedCrossRef
130.
Doll H, Grey-Amante P, Duprat-Lomon I, et al. Quality of life in acute exacerbation of chronic bronchitis: results from a German population study. Respir Med 2002; 96(1): 39–51PubMedCrossRef
131.
132.
Neralla S, Meyer KC. Drug treatment of pneumococcal pneumonia in the elderly. Drugs Aging 2004; 21(13): 851–64PubMedCrossRef
133.
Turnheim K. When drug therapy gets old: pharmacokinetics and pharmacodynamics in the elderly. Exp Gerontol 2003; 38(8): 843–53PubMedCrossRef
134.
Snow V, Lascher S, Mottur-Pilson C, et al. Evidence base for management of acute exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 2001; 134(7): 595–9PubMed
135.
Pea F, Pavan F, Lugatti E, et al. Pharmacokinetic and pharmacodynamic aspects of oral moxifloxacin 400 mg/day in elderly patients with acute exacerbation of chronic bronchitis. Clin Pharmacokinet 2006; 45(3): 287–95PubMedCrossRef
136.
Sin DD, Tu JV. Outpatient antibiotic therapy and short term mortality in elderly patients with chronic obstructive pulmonary disease. Can Respir J 2000; 7(6): 466–71PubMed
137.
Sullivan JT, Lettieri JT, Liu P, et al. The influence of age and gender on the pharmacokinetics of moxifloxacin. Clin Pharmacokinet 2001; 40Suppl. 1: 11–8PubMedCrossRef
138.
Cazzola M, Matera MG, Donnarumma G, et al. Pharmacodynamics of levofloxacin in patients with acute exacerbation of chronic bronchitis. Chest 2005; 128(4): 2093–8PubMedCrossRef
139.
Garcia-Aymerich J, Lange P, Benet M, et al. Regular physical activity reduces hospital admission and mortality in chronic obstructive pulmonary disease: a population based cohort study. Thorax 2006; 61(9): 772–8PubMedCrossRef
140.
Paz-Diaz H, Montes de Oca M, Lopez JM, et al. Pulmonary rehabilitation improves depression, anxiety, dyspnea and health status in patients with COPD. Am J Phys Med Rehabil 2007; 86(1): 30–6PubMedCrossRef
141.
Poole PJ, Chacko E, Wood-Baker RW, et al. Influenza vaccine for patients with chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2006; (1): CD002733
142.
Wang CS, Wang ST, Lai CT, et al. Impact of influenza vaccination on major cause-specific mortality. Vaccine 2007 Jan 26; 25(7): 1196–203PubMedCrossRef
143.
Granger R, Walters J, Poole PJ, et al. Injectable vaccines for preventing pneumococcal infection in patients with chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2006; (4): CD001390
Metadata
Title
Acute Exacerbations of Chronic Bronchitis in Elderly Patients
Pathogenesis, Diagnosis and Management
Authors
Don Hayes Jr
Dr Keith C. Meyer
Publication date
01-07-2007
Publisher
Springer International Publishing
Published in
Drugs & Aging / Issue 7/2007
Print ISSN: 1170-229X
Electronic ISSN: 1179-1969
DOI
https://doi.org/10.2165/00002512-200724070-00004

Other articles of this Issue 7/2007

Drugs & Aging 7/2007 Go to the issue

Leading Article

Neuroprotective Effects of Free Radical Scavengers in Stroke

Review Article

Sustained-Release Ophthalmic Drug Delivery Systems for Treatment of Macular Disorders

Original Research Article

Characterisation of Patients with Postmenopausal Osteoporosis in French Primary Healthcare

Current Opinion

Clinical Perspectives on Bone Quality in Osteoporosis

Therapy In Practice

Epidemiology and Management of Apathy in Patients with Alzheimer’s Disease

Review Article

Glucosamine and Chondroitin Sulfate as Therapeutic Agents for Knee and Hip Osteoarthritis
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits